Journal
ADVANCED HEALTHCARE MATERIALS
Volume 10, Issue 5, Pages -Publisher
WILEY
DOI: 10.1002/adhm.202000802
Keywords
iodine-131; persistent luminescence nanoparticles; photodynamic therapy; radiotherapy; ZnPcC4
Funding
- National Key Research and Development Program of China [2016YFA0203600]
- National Natural Science Foundation of China [81971738, 81571707, 81571743]
- Project Program of State Key Laboratory of Natural Medicines from China Pharmaceutical University [SKLNMZZ202010]
- Fujian medical innovation project [2019-CXB-32]
Ask authors/readers for more resources
A novel I-131 labeled nanoplatform with Cerenkov radiation capability was developed for radiotherapy and radiation-induced photodynamic therapy, showing excellent tumor inhibition in both in vitro and in vivo models. The combination of self-activated PDT and RT has the potential to greatly benefit deep tumor therapy.
Radionuclide with Cerenkov radiation (CR) can serve as an internal excitation source to activate photosensitizers for photodynamic therapy (PDT) in deep tumor. However, the low efficiency of CR limits its therapeutic efficacy. A(131)I labeled zinc tetra(4-carboxyphenoxy) phthalocyaninate (ZnPcC4) conjugated Cr3+-doped zinc gallate (ZnGa2O4:Cr3+, ZGCs) nanoplatform (I-131-ZGCs-ZnPcC4) is developed for radiotherapy (RT) and radiation-induced PDT.I-131 can not only activate ZGCs for long-lasting luminescence via both Cerenkov luminescence (CL) and ionizing radiation, which further continuously activate photosensitizer ZnPcC4 for PDT, but also can directly kill cancerous cells. This(131)I-ZGCs-ZnPcC4 exhibits excellent tumor inhibition both in vitro and in vivo. Combining self-activated PDT and RT, it is believed that the(131)I-ZGCs-ZnPcC4 can greatly benefit the deep tumor therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available